Elite in Multiple System Atrophy

Olivier Rascol

Toulouse, FR 
Clinical Trials:Currently Recruiting for 1 Trial
Elite in Multiple System Atrophy
Toulouse, FR 
OverviewLocationsClinical Research

Overview

Olivier Rascol practices in Toulouse, France. Mr. Rascol is rated as an Elite expert by MediFind in the treatment of Multiple System Atrophy. His top areas of expertise are Parkinson's Disease, Movement Disorders, Multiple System Atrophy, Familial Dysautonomia, and Deep Brain Stimulation.

His clinical research consists of co-authoring 278 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 50 articles and participated in 2 clinical trials in the study of Multiple System Atrophy.

Gender
Male

Locations

Toulouse, France
Other Locations
Equipe 01-Neuropsychologie Interventionnelle L'Institut Mondor De Recherches Biomédicales, Université Paris Est Créteil, UMR 1239, CIC 1413, CIC 1402, CNRS UMR 7104, CIC 1414, CHU De Caen, Caen, France
Clermont-ferrand, France
Strasbourg, France
NS Park French Network, Lille, France
Paris, France
France
Paul, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of ION464 Administered Intrathecally to Adults With Multiple System Atrophy
A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of ION464 Administered Intrathecally to Adults With Multiple System Atrophy
Enrollment Status: Recruiting
Publish Date: November 12, 2024
Intervention Type: Drug
Study Drug: BIIB101
Study Phase: Phase 1
Study of Pimavanserin Efficacy for the Treatment of Impulse Control Disorders in Parkinson's Disease
Study of Pimavanserin Efficacy for the Treatment of Impulse Control Disorders in Parkinson's Disease
Enrollment Status: Completed
Publish Date: January 01, 2025
Intervention Type: Drug, Procedure, Behavioral
Study Drug: Pimavanserin
Study Phase: Phase 2
A Dose-Ranging Study of the Efficacy, Safety, and Pharmacokinetics of Deferiprone Delayed Release Tablets in Patients With Parkinson's Disease
A Dose-Ranging Study of the Efficacy, Safety, and Pharmacokinetics of Deferiprone Delayed Release Tablets in Patients With Parkinson's Disease
Enrollment Status: Completed
Publish Date: April 10, 2024
Intervention Type: Drug
Study Phase: Phase 2
Predictive Factors for Therapeutic Response of Subthalamic Stimulation on Quality of Live in Parkinson's Disease
Predictive Factors for Therapeutic Response of Subthalamic Stimulation on Quality of Live in Parkinson's Disease
Enrollment Status: Active_not_recruiting
Publish Date: November 07, 2022
Intervention Type: Other
Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease. European Multicentre, Parallel-group, Placebo-controlled, Randomized Clinical Trial of Deferiprone
Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease. European Multicentre, Parallel-group, Placebo-controlled, Randomized Clinical Trial of Deferiprone
Enrollment Status: Completed
Publish Date: November 07, 2022
Intervention Type: Drug
Study Drug: Deferiprone
Study Phase: Phase 2
Impact of Amantadine on L-DOPA-induced Dyskinesia in Early Parkinson's Disease: a Placebo-controlled Randomized Study (the PREMANDYSK Study)
Impact of Amantadine on L-DOPA-induced Dyskinesia in Early Parkinson's Disease: a Placebo-controlled Randomized Study (the PREMANDYSK Study)
Enrollment Status: Completed
Publish Date: February 05, 2021
Intervention Type: Drug
Study Phase: Phase 2
Safety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime Sleepiness
Safety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime Sleepiness
Enrollment Status: Completed
Publish Date: December 01, 2020
Intervention Type: Drug
Study Phase: Phase 2
Treatment of Severe and Resistant Obsessive-compulsive Disorder by High-frequency Stimulation of the Ventral Striatum and the Subthalamic Nucleus
Treatment of Severe and Resistant Obsessive-compulsive Disorder by High-frequency Stimulation of the Ventral Striatum and the Subthalamic Nucleus
Enrollment Status: Completed
Publish Date: February 06, 2020
Intervention Type: Procedure
Study Phase: Phase 3
Morphological and Functional Investigation of the Serotoninergic System in Multiple System Atrophy: a 18F-MPPF PET Study
Morphological and Functional Investigation of the Serotoninergic System in Multiple System Atrophy: a 18F-MPPF PET Study
Enrollment Status: Completed
Publish Date: August 04, 2017
Intervention Type: Other, Drug, Radiation
Double-Blind Randomized Placebo-Controlled Cross-Over Phase IIa Trial to Evaluate Efficacy of CVXL-0107 on Parkinson-Related Symptoms and Levodopa-Induced Dyskinesia in Advanced Parkinson's Disease Patients Using a Levodopa Challenge Test
Double-Blind Randomized Placebo-Controlled Cross-Over Phase IIa Trial to Evaluate Efficacy of CVXL-0107 on Parkinson-Related Symptoms and Levodopa-Induced Dyskinesia in Advanced Parkinson's Disease Patients Using a Levodopa Challenge Test
Enrollment Status: Completed
Publish Date: July 24, 2017
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

278 Total Publications

Correction: Opicapone for the treatment of early wearing-off in levodopa-treated Parkinson's disease: pooled analysis of patient level data from two randomized open-label studies.
Correction: Opicapone for the treatment of early wearing-off in levodopa-treated Parkinson's disease: pooled analysis of patient level data from two randomized open-label studies.
Journal: Journal of neurology
Published: August 01, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Rascol's expertise for a condition
ConditionClose
View All 7 Elite Conditions
View All 21 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile